Overview
Acute myelocytic leukemia (AML), also known as acute
myelogenous leukemia is a type of cancer that affects the blood and the bone
marrow. Immature white blood cells accumulate in the bone marrow thus blocking
the production of normal blood cells. These cells further enter the blood
stream and spread to the other parts of the body. Symptoms for AML include
fatigue, fever, bleeding, breathing problems, weight loss. The predisposing
factors involved are exposure to radiation or chemicals and smoking. Treatment
includes chemotherapy, transfusions, transplant and surgery.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555334-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-pipeline-review-h1-2017
Report
Highlights
The Pharmaceutical and Healthcare latest pipeline guide Acute
Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1
2017, provides comprehensive information on the therapeutics under development
for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology),
complete with analysis by stage of development, drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete research
and development history and latest news and press releases.
The Acute Myelocytic Leukemia (AML, Acute Myeloblastic
Leukemia) (Oncology) pipeline guide also reviews of key players involved in
therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic
Leukemia) and features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes, the
molecules developed by Companies in Pre-Registration, Filing
rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed,
Preclinical, Discovery and Unknown stages are 5, 1, 18, 98, 105, 1, 5, 171, 14
and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I,
Preclinical and Discovery stages comprises 16, 14, 31 and 13 molecules,
respectively.
Major Scope of the report:
- The pipeline guide provides a snapshot of the global
therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic
Leukemia) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
Table of Contents
Introduction 10
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview 11
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development 12
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment 71
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development 100
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles 218
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects 1600
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products 1612
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones 1616
Appendix 1628
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview 11
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development 12
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment 71
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development 100
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles 218
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects 1600
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products 1612
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones 1616
Appendix 1628
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555334-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-pipeline-review-h1-2017
About Us
Wise Guy
Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium
progressive statistical surveying, market research reports, analysis &
forecast data for industries and governments around the globe. Wise Guy Reports
understand how essential statistical surveying information is for your
organization or association. Therefore, we have associated with the top
publishers and research firms all specialized in specific domains, ensuring you
will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner
Relations & Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208
133 9349 (UK)
